ERBB2 and breast carcinoma: The phase III study AVEREL (Avastin [Bevacizumab] in Combination With Herceptin [Trastuzumab]/Docetaxel in Patients With HER2-Positive Metastatic Breast Cancer) enrolled 424 patients with HER2-positive metastatic breast cancer who were randomly assigned to docetaxel plus trastuzumab with or without bevacizumab.